Peptides
Ipamorelin
Selective Growth Hormone Secretagogue
Category
GH peptide
Half-life
~2 hours
Typical dose
200–300 mcg
Frequency
2–3× daily
Route
Subcutaneous injection
Mechanism
Ipamorelin is a selective growth hormone secretagogue receptor (GHSR) agonist — a synthetic ghrelin mimetic. It stimulates pituitary GH release with high selectivity, producing minimal elevation of cortisol, prolactin, or ACTH compared to older GHRPs. This selectivity makes it favorable for research protocols requiring GH stimulation without the side effects of less selective secretagogues.
Research summary
Ipamorelin is considered one of the cleanest GHRPs due to its selectivity profile. Combined with CJC-1295, it produces synergistic GH pulses. Pre-sleep dosing aligns with natural GH release during slow-wave sleep.
Storage
Lyophilized: −20°C. Reconstituted: 2–8°C up to 4 weeks.
Key studies
Raun K, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. DOI: 10.1530/eje.0.1390552
Frequently asked questions
What makes ipamorelin different from other GHRPs?
Ipamorelin is highly selective — it stimulates GH release without significantly elevating cortisol, prolactin, or ACTH. Older GHRPs like GHRP-6 cause cortisol and prolactin spikes. Ipamorelin's selectivity makes it preferable for most research protocols.
When should ipamorelin be dosed?
Pre-sleep dosing is most common, aligning with the natural GH pulse during slow-wave sleep. Fasting 2–3 hours before dosing maximizes response — insulin blunts GH release.
For research use only. Not intended for human consumption. Not medical advice. Consult a licensed physician before use.